Pharma Focus Europe

BioInvent Enters Clinical Trial Collaboration and Supply Agreement with MSD to Assess BI-1910 Combined with KEYTRUDA®

Tuesday, April 02, 2024

BioInvent International AB (Nasdaq Stockholm: BINV), a biotechnology company specializing in the development of innovative immune-modulatory antibodies for cancer immunotherapy, has announced a collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The agreement is for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA® (pembrolizumab).

Under this agreement, MSD will supply its anti-PD-1 therapy KEYTRUDA to be used alongside BI-1910 in the trial. The Phase 1/2a trial will be conducted in both the US and Europe, featuring an innovative, adaptive design to facilitate optimal dose escalation.

BI-1910 represents BioInvent’s second venture into clinical development within the tumor necrosis factor receptor 2 (TNFR2) program, following BI-1808, which is currently in Phase 2a. BI-1910 is differentiated by its agonist approach to cancer treatment compared to BI-1808. Both monoclonal antibodies were carefully selected from a range of binders generated through BioInvent’s proprietary F.I.R.S.T™ technology platform. The Phase 1/2a study's single-agent arm began in December 2023, with initial data expected by the end of 2024.

Martin Welschof, CEO of BioInvent, expressed enthusiasm about the collaboration, stating, "We are delighted to partner with MSD to explore the unique attributes of BI-1910 combined with KEYTRUDA. This trial will leverage our deep understanding of TNFR2 biology as we advance two distinct monoclonal antibodies through clinical evaluation. With our fifth product in ongoing clinical trials, BioInvent’s technology demonstrates its ability to identify novel therapeutic cancer targets."

(KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.)

 

Source: bioinvent.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva